Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,655.33GBp
3:44am EST
Change (% chg)

-15.00p (-0.90%)
Prev Close
1,670.00p
Open
1,678.00p
Day's High
1,678.00p
Day's Low
1,653.00p
Volume
34,985
Avg. Vol
738,947
52-wk High
2,703.00p
52-wk Low
1,575.00p

Select another date:

Tue, Nov 22 2016

BRIEF-Hikma announces U.S. deal with Vectura for generic salmeterol development

* Announces agreement with Vectura for development of generic salmeterol for U.S. market Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Hikma Pharmaceuticals sees FY group revenue to grow by about 35 pct

* In US, good demand across a number of products and new product launches has more than offset increased competition for certain products

BUZZ-Hikma: top Stoxx loser as HSBC cuts TP on DoJ market probe

** Hikma Pharma -c.7% in heavy vols, biggest loser on Stoxx & trading at lowest in 10 mnths as HSBC cuts TP to 1985p from 2525p

BRIEF-Hikma says first-half revenue up 28 pct

* H1 group core operating profit of $176 mln, down 14 pct and down 3 pct in constant currency

BRIEF-Hikma sees FY revenue between $2-$2.1 bln

* Continue to expect group revenue to be in range of $2.0 bln to $2.1 bln for full year

BRIEF-Hikma says U.S. Court of Appeals upholds regulatory approval of colchicine

* Fda's regulatory approval of hikma's colchicine 0.6 mg capsule product was upheld.

BRIEF-Hikma Pharma announces U.S. launch of two generic tablets

* Announces launch of generic xeloda tablets 150 mg and 500 mg in US Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Court dismisses Takeda's bid to block Hikma gout drug sales

By Brendan Pierson A federal appeals court has dismissed a bid by Takeda Pharmaceutical Co to halt sales of Hikma Pharmaceuticals PLC's gout drug Mitigare, which has the same active ingredient as Takeda's Colcrys.

Hikma seeks dismissal of Takeda's bid to block gout drug sales

Hikma Pharmaceuticals PLC is asking a federal appeals court to reject a bid by rival Takeda Pharmaceutical Co to halt sales of Hikma's gout drug Mitigare, arguing that the challenge is moot after Hikma won a separate patent case last month.

Select another date: